1615-41-4

Basic information

• Product Name: sulfuridazole
• Synonyms: sulfuridazole;1-methyl-2-(methylthio)-5-nitro-1H-imidazole;1H-Imidazole,1-methyl-2-(methylthio)-5-nitro-
• CAS NO: 1615-41-4
• Molecular Formula: C5H7N3O2S
• Molecular Weight: 173.19298
• Mol File: 1615-41-4.mol

Chemical Properties

• Melting Point: 86-88 °C
• Boiling Point: 350.2°Cat760mmHg
• Flash Point: 165.6°C
• Appearance: /
• Density: 1.46g/cm³
• Vapor Pressure: 4.48E-05mmHg at 25°C
• Refractive Index: 1.651
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 0.93±0.25(Predicted)
• CAS DataBase Reference: sulfuridazole(CAS DataBase Reference)
• NIST Chemistry Reference: sulfuridazole(1615-41-4)
• EPA Substance Registry System: sulfuridazole(1615-41-4)

Safety Data

• Hazardous Substances Data: 1615-41-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Sulfuridazole is used as an antibacterial agent for treating bacterial infections, particularly those caused by anaerobic bacteria. It is effective against infections in the gastrointestinal tract, urogenital system, and respiratory system.
Used in Gynecological Treatments:
Sulfuridazole is used as a treatment for bacterial vaginosis, a common vaginal infection, due to its ability to target anaerobic bacteria.
Used in Parasitic Infections:
Sulfuridazole is used as a treatment for trichomoniasis, a parasitic infection, as it can effectively eliminate the causative protozoan parasite.
Used in Amoebiasis Treatment:
Sulfuridazole is used as a medication for amoebiasis, an infection caused by the amoeba Entamoeba histolytica, helping to control and eliminate the infection.
Administered Orally:
Sulfuridazole is used as an orally administered medication, making it a convenient and accessible treatment option for various bacterial infections.
Well-Tolerated with Common Side Effects:
Sulfuridazole is generally well-tolerated, with common side effects including nausea, vomiting, and diarrhea, which highlights the importance of following prescribed dosages and guidance from healthcare professionals.
Preventing Bacterial Resistance:
It is crucial to use sulfuridazole only as prescribed by a healthcare professional to prevent the development of bacterial resistance, ensuring the ongoing effectiveness of this antibiotic.

InChI:InChI=1/C5H7N3O2S/c1-7-4(8(9)10)3-6-5(7)11-2/h3H,1-2H3

Upstream product

• 14486-52-3 2-methylmercapto-3-methylimidazole 

Downstream Products

• 1615-53-8 1-methyl-2-methylsulphonyl-5-nitro-imidazole 
• 56302-26-2 2-methanesulfinyl-1-methyl-5-nitro-1H-imidazole 

Relevant articles and documents

Synthesis, characterization, crystallographic analysis, antifungal and genotoxic properties of some 1-methyl-1H-imidazoles

A number of 1-methyl-1H-imidazole derivatives and some of their oxygenated products were synthesized. An HPTLC technique for following the oxidation reactions in the different experimental conditions used was applied. The X-ray crystal structures of 1-methyl-2-methylsulfanyl-5-nitro-1H-imidazole, 2-methanesulfinyl-1-methyl-5-nitro-1H-imidazole and 2-methanesulfonyl-1-methyl-5-nitro-1H-imidazole were determined. The compounds obtained were investigated for antimycotic and genotoxic activities. The compounds tested were found to exert very low growth inhibition against yeasts and moulds. Moderate antifungal properties against dermatophytes were demonstrated for 5-nitro derivatives. 2-Methanesulfonyl-1-methyl-5-nitro-1H-imidazole was the mos active substance. All 5-nitroimidazoles were genotoxic in Bacillus subtilis rec-assay, Salmonella microsome test and in Saccharomyces cerevisiae mitotic segregation assay. Structure-activity relationships are discussed.

Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead

As part of our efforts to develop new compounds aimed at the therapy of parasitic infections, we synthesized and assayed analogues of a lead compound megazol, 5-(1-methyl-5-nitro-1H-2-imidazolyl)-1,3,4-thiadiazol-2-amine, CAS no. 19622-55-0), in vitro. We first developed a new route for the synthesis of megazol. Subsequently several structural changes were introduced, including substitutions on the two rings of the basic nucleus, replacement of the thiadiazole by an oxadiazole, replacement of the nitroimidazole part by a nitrofurane or a nitrothiophene, and substitutions on the exocyclic nitrogen atom for evaluation of an improved import by the glucose or the purine transporters. Assays of the series of compounds on the protozoan parasites Trypanosoma brucei, Trypanosoma cruzi, and Leishmania donovani, as either extracellular cells or infected macrophages, indicated that megazol was more active than the derivatives. Megazol was then evaluated on primates infected with Trypanosoma brucei gambiense, including late-stage central nervous system infections in combination with suramin. Full recovery was observed in five monkeys in the study with no relapse of parasitemia within a 2 year follow-up. Because there is a lack of efficacious treatments for sleeping sickness in Africa and Chagas disease in South America, megazol is proposed as a potential alternative. The mutagenicity of this compound is at present being reevaluated, and metabolism is also under investigation prior to possible further developments.